Imatinib (Gleevec) has activity in AIDS-related Kaposi's sarcoma

Alexandria, VA--A new clinical study has shown that imatinib mesylate (Gleevec) has activity in AIDS-related Kaposi's sarcoma (KS). Imatinib inhibits important pathways that spur cancer growth, resulting in the regression of KS tumors within 4 weeks in some patients. The study will be published November 30 in the Journal of Clinical Oncology (JCO).

"Imatinib is a targeted therapy originally shown to be effective in treating chronic myelogenous leukemia and gastrointestinal stromal tumors. This study and others are showing that the drug is also active in other cancers that express some of the same proteins," said Henry B. Koon, MD, Instructor of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, and lead author of the study. "Studies like this one represent an exciting time in oncology, when our understanding of the development of diseases like KS coincide with the availability of effective treatments. Further research on imatinib in KS patients will be needed to determine appropriate dosing schedules."

Kaposi's sarcoma is an AIDS-defining illness characterized by soft purplish lesions on the skin, mucous membranes, and internal organs. Although the incidence of KS has declined dramatically in the developed world since the advent of highly active antiretroviral therapies (HAART), it remains a significant cause of morbidity and mortality for AIDS patients in the United States and a major cause of mortality in the third world, given the limited number of effective treatments for KS.

Researchers examined the response of Kaposi's sarcoma to imatinib, a drug known to inhibit the PDGF-R and/or c-kit pathways that are responsible for the growth of other cancers, such as chronic myelogenous leukemia, gastrointestinal stromal tumors (GIST), and bone sarcomas of the head and neck. Given that PDGF-R and c-kit also play a role in the development of KS, researchers theorized that imatinib may be an effective strategy

Contact: Danielle Potuto
American Society of Clinical Oncology

Page: 1 2

Related medicine news :

1. Imatinib shows early promise against Ewings sarcoma
2. Brain activity prior to treatment flags vulnerability to antidepressant side effects
3. Physical activity linked to protection from Parkinsons disease
4. Brain activity of men and women during hostile or impulsive acts differs less on nicotine
5. Abnormal brain activity during the observation of others actions
6. Increased physical activity not linked to ALS risk
7. Maintaining physical activity linked to less cognitive decline in older men
8. Daily social/physical activity improves sleep and cognition in the elderly
9. Celecoxib shows surprising activity against estrogen receptors
10. Jefferson scientists find way to see breast cancer activity from outside the body
11. Brain activity reflects complexity of responses to other-race faces

Post Your Comments:

(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... National recruitment ... a life sciences executive with extensive sequencing and genomics experience, as Vice President of ... position, Ms. Hill will be responsible for leading the sales team in the commercialization ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology:
Cached News: